3,680 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Bought by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC bought a new position in Ascendis Pharma A/S (NASDAQ:ASND) in the fourth quarter, HoldingsChannel.com reports. The firm bought 3,680 shares of the biotechnology company’s stock, valued at approximately $507,000.

Other large investors have also recently added to or reduced their stakes in the company. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S in the third quarter valued at about $60,000. Janus Henderson Group PLC lifted its stake in Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new position in Ascendis Pharma A/S during the 3rd quarter worth approximately $19,908,000. Zimmer Partners LP bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth approximately $11,646,000. Finally, American Century Companies Inc. raised its holdings in shares of Ascendis Pharma A/S by 17.5% in the fourth quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company’s stock valued at $56,072,000 after purchasing an additional 60,548 shares during the last quarter.

Analysts Set New Price Targets

ASND has been the subject of several recent research reports. Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. The Goldman Sachs Group increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Cantor Fitzgerald raised their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, February 25th. JPMorgan Chase & Co. upped their target price on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a report on Tuesday, March 18th. Finally, Evercore ISI raised their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, February 18th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus target price of $204.64.

Ascendis Pharma A/S Trading Down 2.8 %

Shares of NASDAQ ASND opened at $151.43 on Wednesday. The business’s 50 day moving average is $145.13 and its 200-day moving average is $137.86. The firm has a market cap of $9.19 billion, a P/E ratio of -21.33 and a beta of 0.61. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. Analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.